Stabilized tibolone compositions
OwnerPieter de Haan, Theodora Antonia Maria Lambregts v.d. Hurk +3inventors
InventorsPieter de Haan, Theodora Antonia Maria Lambregts v.d. Hurk, Ryoichi Morita, Adrianus Cornelis Petrus Rovers, Jocominus Antonius Maria Zwinkels
Life of this patent
Estimating the term…
Abstract
A stabilized pharmaceutical dosage unit comprising tibolone, in an amount of from 0.1% to 10% by weight of the dosage unit, and a pharmaceutically acceptable carrier. The carrier comprising lactose in an amount at least 47% to 90% by weight of the dosage unit. A stabilized pharmaceutical dosage unit comprising tibolone, in an amount of from 0.1% to 10% by weight of the dosage unit, and a pharmaceutically acceptable carrier. The dosage unit is contained in a humid atmosphere of 50 to 70% relative humidity until administration.
Claims12
A pharmaceutical dosage unit comprising tibolone, in an amount of from 0.1 to 10% by weight, and a pharmaceutically acceptable carrier, the carrier containing a water-insoluble starch product, characterised in that the starch content in the carrier is more than 10% by weight.
A dosage unit according to any one of the preceding claims, characterised in that the starch product is selected from the group consisting of Starch 1500, potato starch, corn starch, wheat starch, and mixtures thereof, the group including modified starches, agglomerated starches, and granulated starches.
A dosage unit according to any one of the preceding claims, characterised in that the tibolone is present in an amount of 2% by weight or less.
A dosage unit according to any one of the preceding claims, characterised in that it contains up to 5% by weight of a stabiliser selected from the group consisting of antioxidants, chelating agents, and mixtures thereof.
A method of making a dosage unit according to any one of the preceding claims, the method comprising the steps of providing a carrier of the desired composition, mixing tibolone, and optionally stabilising agents, with a portion of the eventually needed amount of carrier to obtain a pre-mix, screening the pre-mix, further mixing it with the remaining portion of the carrier, and finally admixing with lubricant.
The use of a starch product as a carrier for pharmaceutical dosage units comprising tibolone for the purpose of increasing the stability of the tibolone.
Dependencies are inferred from the claim text.